# OnCo record solo-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/solo-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "solo-1", "NCT01844986" ;
  schema:name "SOLO-1"@en ;
  schema:description "Two years of an olaparib pill after chemotherapy made a large share of women with BRCA-mutated ovarian cancer long-term survivors."@en ;
  schema:url <https://onco.cc/trials/solo-1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01844986>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1810858>, <https://ascopubs.org/doi/10.1200/JCO.22.01549> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2013-08-26" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/kathleen-moore/> .